NST002 Phase IIa Study (ALS) Promising Results Continue Reports NeuroSense Post author:Medical Device News Magazine Post published:November 18, 2020 Post category:CLINICAL TRIALS, STUDIES, REGISTRIES, DATA The study is set to be completed in January of 2021, following 12-months dosing. Continue ReadingNST002 Phase IIa Study (ALS) Promising Results Continue Reports NeuroSense